Evaluating the Treatment of Diabetic Macular Edema with Aflibercept Based on a Regional Network of Ophthalmologic Care Givers
Purpose. In Austria, anti-VEGF therapies are reimbursed only in clinical settings. This study aimed to describe the outcome of a treat and extend regimen (TER) with aflibercept for diabetic macular edema (DME) in a network of practitioners. Methods. In a prospective study over 36 months, patients wi...
Saved in:
Main Authors: | Haidar Khalil, Siegfried Mariacher, Rupert Strauss, Dominika Podkowinski, Klemens Waser, Matthias Bolz |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-01-01
|
Series: | Journal of Ophthalmology |
Online Access: | http://dx.doi.org/10.1155/2023/3165965 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy
by: Filipe Mira, et al.
Published: (2017-01-01) -
Coats’ Disease-Related Macular Edema Treated with Combined Aflibercept and Laser Photocoagulation
by: Wen-Shi Shieh, et al.
Published: (2017-01-01) -
Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
by: Ali Demircan, et al.
Published: (2018-01-01) -
Intravitreal Aflibercept as a Rescue Therapy for Retinal Neovascularization and Macular Edema due to Eales Disease
by: Ning-Yi Hsia, et al.
Published: (2021-01-01) -
Clinical Comparative Study of Intravitreal Injection of Triamcinolone Acetonide and Aflibercept in the Treatment of Diabetic Retinopathy Cystoid Macular Edema
by: Yanxia Zhu, et al.
Published: (2022-01-01)